- Issuer ticker
-
EIKN
- Reported as of
-
02 Mar 2026
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
4
- Accepted by SEC
-
04 Mar 2026, 17:02:00 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Benjamin Thorner, Attorney-in-Fact
Filing notes and source
Key filing fact
Robert Luther Huffines filed Form 4 for Eikon Therapeutics, Inc. (EIKN) on 04 Mar 2026.
Key facts
- This page summarizes Robert Luther Huffines's Form 4 filing for Eikon Therapeutics, Inc. (EIKN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Mar 2026, 17:02.
Change
- Previous filing in this sequence was filed on 05 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001728221
Primary reporting owner
Huffines Robert Luther
- Relationship
-
Director
- Address
- C/O EIKON THERAPEUTICS, INC., 230 HARRIET TUBMAN WAY, MILLBRAE
- Signature
- /s/ Benjamin Thorner, Attorney-in-Fact
- Signature date
- 04 Mar 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EIKN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +25,873
- Change %
- Price
-
$0.000000*
- Shares after
- 25,873
- Date
- 02 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,873
- Exercise price
- $14.88
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote